Eirion Therapeutics
AI-09 — a ready-to-use liquid injectable recombinant BoNT-A — achieved clinically and statistically significant results with a 26-week median duration at the highest dose in a 96-subject Phase 1-2 trial (October 2024, four US investigational sites), entered Phase 2 (NCT07321834) in December 2025;…
- Country
- United States
$40M Haohai Biological Technology licensing deal; HTL Biotechnology (FR) manufacturing
us
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Recombinant botulinum toxin (biosynthetic Botox) | specialty-fine-chem | Low | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.